28 February 2020 - Potential first product in Europe for the prevention of cisplatin-induced hearing loss in children.

Fennec Pharmaceuticals today announced that the company’s marketing authorisation application for its investigational drug, sodium thiosulphate (unique formulation) for infusion, has passed validation and is now under evaluation by the EMA. 

The application was filed in early February 2020 for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localised, non-metastatic, solid tumours.